Bladder cancer is the tenth most common cancer worldwide and the seventh most common among men. In Catalonia, around 3,400 new cases are diagnosed each year, according to data from the Oncology Master Plan, with an incidence approximately four times higher in men than in women. Despite these figures, bladder cancer remains relatively invisible at a social level. One reason is that its early symptoms—particularly the presence of blood in the urine—can be mistaken for benign conditions or go unnoticed, often delaying medical consultation and diagnosis.
Smoking, the main risk factor for bladder cancer
Smoking is by far the main risk factor for bladder cancer and is estimated to account for around half of all cases. Toxic substances from tobacco are absorbed through the lungs, enter the bloodstream and are eliminated in the urine, where they come into contact with the bladder lining. Smokers have a three- to fourfold higher risk than non-smokers. Quitting smoking is the most effective preventive measure, although its effects persist for years, meaning that former smokers should also remain vigilant.
Knowing the symptoms of bladder cancer and seeking medical advice early
The most common warning sign is blood in the urine, often painless and intermittent. Other symptoms may include discomfort when urinating, urgency or the need to urinate much more frequently than usual. Any of these symptoms—especially in smokers or former smokers over the age of 50—should prompt a medical consultation without delay. Blood in the urine does not always indicate cancer, but it should always be investigated.
Why early detection of bladder cancer makes a difference
Approximately 75% of bladder cancers are diagnosed at stages in which the tumour has not yet invaded the bladder muscle. When detected at this point, treatment is less aggressive and the prognosis is generally favourable. Early detection therefore makes a real difference for patients.
Early detection research on bladder cancer at Hospital Clínic
At the Uro-oncology Unit of Hospital Clínic, together with Dr Antoni Vilaseca and a multidisciplinary team, we are developing a clinical research project funded by the Carlos III Health Institute (FIS) focused on the early detection of bladder cancer in at-risk populations. The study is assessing whether automated analysis of urinary sediment can help identify the disease in asymptomatic individuals—smokers and former smokers aged 50 to 70—using a urine sample, without radiation or invasive tests. The aim is to help define future early detection strategies tailored to this group.
Today, on World Bladder Cancer Day, we are reminded that raising awareness, prevention and early detection are three steps within everyone’s reach.
